Progenics Pharmaceuticals Announces Fourth Quarter and Year-End 2012 Financial
TARRYTOWN, N.Y., March 15, 2013 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals,
Inc. (Nasdaq:PGNX) today announced its results of operations for the fourth
quarter and year end 2012.
Net loss for the fourth quarter was $0.3 million or $0.01 diluted per share,
compared to net loss of $10.7 million or $0.32 diluted per share in the 2011
period. Net loss for the year was $35.4 million or $1.02 diluted per share,
compared to net income of $10.4 million or $0.31 diluted per share in 2011.
The 2012 results include revenue from partnering two proprietary research
programs, while 2011 results reflect upfront payment and reimbursement revenue
from the company's Relistor^® collaboration with Salix Pharmaceuticals. At
December 31, 2012, Progenics had cash, cash equivalents and securities of
$62.1 million, an increase of $17.8 million in the quarter including proceeds
of a fourth quarter follow-on common stock offering and reflecting use of
$11.3 million for the full year.
Fourth quarter revenue totaled $8.9 million, up $6.7 million from the 2011
period, resulting primarily from the partnering transactions. For the full
year, Progenics reported revenues of $14.0 million, compared to $84.8 million
for 2011, a decrease primarily from 2011 recognition of the Salix
Royalty income for the quarter was $0.8 million compared to $1.3 million in
the fourth quarter of 2011, reflecting stocking activity in 2011. Royalty
income for the year was $5.0 million compared to $3.0 million for 2011.
Net sales reported to Progenics by Salix (in millions):
Three Months Ended Year Ended
December 31, September 30, December 31,
2012 2011 2012 2012 2011
U.S. $4.1 $8.0 $3.8 $29.2 $21.5
Ex-U.S. 1.1 0.8 1.1 4.0 5.5
Global $5.2 $8.8 $4.9 $33.2 $27.0
Fourth quarter and full year research and development expenses decreased by
$2.4 million and $20.7 million, respectively, compared to the 2011 periods,
primarily from reduced headcount and decreased laboratory, manufacturing and
operating expenses. Clinical trial expenses increased in the fourth quarter
compared to the 2011 period and decreased for the full year. Fourth quarter
general and administrative expenses decreased $1.1 million from 2011; full
year G&A expense was down $3.5 million, in each case due to lower consulting,
compensation and other operating expense. Company-wide headcount as of
December 31, 2012 declined to 76 from 105 as of December 31, 2011.
Fourth Quarter Highlights
*Completed underwritten public offering of 12,650,000 primary common shares
resulting in $23.3 million net proceeds.
*Out-licensed C. difficile preclinical program for $5.0 million upfront
payment (received in January) with potential future milestones and
*Fourth quarter Relistor global net sales increased 8% from the third
quarter, but decreased 40% from the prior year period due to 2011 stocking
activity. Annual Relistor global net sales increased 23% over 2011.
*Acquired Molecular Insight Pharmaceuticals, expanding our oncology
pipeline with diagnostic and small molecule therapeutic candidates
targeting PSMA and prostate cancer.
*Reported positive clinical data from a study of two novel radiolabeled
small molecule imaging agents – ^123I-MIP-1072 and ^123I-MIP-1095 –
Conference Call and Webcast
Progenics will review fourth quarter and year-end financial results in a
conference call today at 8:30 a.m. EDT. To participate, please dial (877)
250-8889 (domestic) or (720) 545-0001 (international) and reference conference
ID 21225492. A live webcast will be available on the Events section of the
Progenics website, www.progenics.com, and a replay will be available on the
website for two weeks.
- Financial Tables follow -
PROGENICS PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except net (loss) income per share)
For the Three Months Ended For the Year Ended
December 31, December 31,
2012 2011 2012 2011
Royalty income $782 $1,279 $4,963 $3,046
Collaboration revenue 8,004 366 8,525 76,764
Research grants 71 464 488 4,810
Other revenues 28 88 72 176
Total revenues 8,885 2,197 14,048 84,796
Research and development 5,423 8,296 31,840 53,183
License fees – research and 510 12 1,170 578
Royalty expense 79 131 499 405
General and administrative 2,953 4,035 14,706 18,248
Depreciation and 261 485 1,324 2,066
Total expenses 9,226 12,959 49,539 74,480
Operating (loss) income (341) (10,762) (35,491) 10,316
Interest income 17 16 60 65
Total other income 17 16 60 65
Net (loss) income before (324) (10,746) (35,431) 10,381
Income tax benefit -- -- -- --
Net (loss) income $(324) $(10,746) $(35,431) $10,381
Net (loss) income per share; $(0.01) $(0.32) $(1.02) $0.31
Weighted average shares 37,590 33,700 34,754 33,375
Net income (loss) per share; $(0.01) $(0.32) $(1.02) $0.31
Weighted average shares 37,590 33,700 34,754 33,494
CONDENSED CONSOLIDATED BALANCE SHEETS
December 31, December 31,
Cash and cash equivalents $58,838 $70,105
Accounts receivable 6,937 1,516
Auction rate securities 3,240 3,332
Fixed assets, net 3,399 4,038
Other assets 3,894 1,119
Total assets $76,308 $80,110
Liabilities $8,902 $7,943
Deferred revenue 838 366
Total liabilities 9,740 8,309
Stockholders' equity 66,568 71,801
Total liabilities and stockholders' equity $76,308 $80,110
Progenics has exclusively licensed development and commercialization rights
for its first commercial product, Relistor, to Salix Pharmaceuticals, Ltd. for
markets worldwide other than Japan, where Ono Pharmaceutical Co., Ltd. holds
an exclusive license for the subcutaneous formulation. Relistor
(methylnaltrexone bromide) subcutaneous injection is a first-in-class
treatment for opioid-induced constipation approved in more than 50 countries
for patients with advanced illness.
Important Safety Information for subcutaneous Relistor
Relistor is indicated for the treatment of opioid-induced constipation (OIC)
in patients with advanced illness who are receiving palliative care, when
response to laxative therapy has not been sufficient. Use of Relistor beyond
four months has not been studied.
Relistor is contraindicated in patients with known or suspected mechanical
gastrointestinal obstruction. If severe or persistent diarrhea occurs during
treatment, advise patients to discontinue therapy with Relistor and consult
their physician. Use of Relistor has not been studied in patients with
Safety and efficacy of Relistor have not been established in pediatric
Rare cases of gastrointestinal (GI) perforation have been reported in advanced
illness patients with conditions that may be associated with localized or
diffuse reduction of structural integrity in the wall of the GI tract (i.e.,
cancer, peptic ulcer, Ogilvie's syndrome). Perforations have involved varying
regions of the GI tract (e.g., stomach, duodenum, colon).
Use Relistor with caution in patients with known or suspected lesions of the
GI tract. Advise patients to discontinue therapy with Relistor and promptly
notify their physician if they develop severe, persistent, and/or worsening
The most common adverse reactions reported with Relistor compared with placebo
in clinical trials were abdominal pain (28.5% vs. 9.8%), flatulence (13.3% vs.
5.7%), nausea (11.5% vs. 4.9%), dizziness (7.3% vs. 2.4%), diarrhea (5.5% vs.
2.4%), and hyperhidrosis (6.7% vs. 6.5%).
Relistor full Prescribing Information for the U.S. is available at
Progenics Pharmaceuticals, Inc. develops innovative medicines for oncology,
and has a pipeline that includes product candidates in preclinical through
late-stage development. Progenics' first commercial product, Relistor^®
(methylnaltrexone bromide) for opioid-induced constipation, is marketed and in
further development by Salix Pharmaceuticals, Ltd. for markets worldwide other
than Japan, where Ono Pharmaceutical Co., Ltd. holds an exclusive license for
the subcutaneous formulation. For additional information, please visit
The Progenics Pharmaceuticals Inc. logo is available at
This press release may contain projections and other forward-looking
statements regarding future events. Such statements are predictions only, and
are subject to risks and uncertainties that could cause actual events or
results to differ materially. These risks and uncertainties include, among
others, the cost, timing and results of clinical trials and other development
activities; the unpredictability of the duration and results of regulatory
review of New Drug Applications and Investigational NDAs; market acceptance
for approved products; generic and other competition; the possible impairment
of, inability to obtain and costs of obtaining intellectual property rights;
and possible safety or efficacy concerns, general business, financial and
accounting matters, litigation and other risks. More information concerning
Progenics and such risks and uncertainties is available on its website, and in
its press releases and reports it files with the U.S. Securities and Exchange
Commission. Progenics is providing the information in this press release as of
its date and does not undertake any obligation to update or revise it, whether
as a result of new information, future events or circumstances or otherwise.
Additional information concerning Progenics and its business may be available
in press releases or other public announcements and public filings made after
For more information, please visit www.progenics.com.
For more information about Relistor, please visit www.relistor.com.
CONTACT: Amy Martini
Press spacebar to pause and continue. Press esc to stop.